CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for YM BioSciences Inc. (USA) is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

YM BioSciences Inc. (USA)
5045 Orbitor Drive
Suite 400, Building 11
Phone: (905) 629-9761p:905 629-9761 Mississauga, ON  L4W 4Y4  Canada Ticker: YMIYMI
This company was Merged or Acquired on 2/8/2013.
This company ceased filing statements with the SEC on 2/22/2013.
This company is no longer actively traded on any major stock exchange.
This is a Subsidiary, click here for the Parent Company
Business Summary
YM BioSciences Inc. (YM), is a drug development company. The Company is advancing three clinical-stage hematology and cancer-related products. Its CYT387, is an oral small molecule oral dual inhibitor of the JAK1/JAK2 kinase; nimotuzumab, an EGFR-targeting monoclonal antibody, and CYT997, a vascular disrupting agent (VDA). The Company conducts and outsources clinical trials and also out source the manufacture of clinical materials to third parties. It focuses to co-develop and/or license the rights to manufacture or market its products in development to other pharmaceutical companies in exchange for license fees and royalty payments. YM’s portfolio contains a library of novel small molecules with development potential.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/20126/30/2012YesYes---

Industries
SIC Code Description
2834 Pharmaceutical preparations
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board David G.Allan 70 11/18/2010 8/23/1994
President, Chief Executive Officer, Director NickGlover 43 11/18/2010 1/1/2010
Vice President - Finance and Administration LeonardVernon 68 1/1/2006 7/1/1997
9 additional Officers and Directors records available in full report.

Business Names
Business Name
Cytopia Limited
YM BIOSCIENCES INC
YMI

General Information
Number of Employees: 32 (As of 6/30/2012)
Outstanding Shares: 157,967,659 (As of 12/31/2012)
Stock Exchange: AMEX
Fax Number: (905) 629-4959


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Saturday, July 22, 2023